Farxiga Cannabis Interaction Profile: What Patients and Clinicians Need to Know

How Dapagliflozin Works and Why Cannabis Matters

Dapagliflozin blocks the sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, causing roughly 70 grams of glucose to be excreted in urine daily [1]. That glucose loss lowers blood sugar without requiring insulin, but it also shifts hepatic metabolism toward ketone production. The FDA-approved prescribing information for Farxiga explicitly identifies diabetic ketoacidosis (DKA) as a risk warranting assessment before and during therapy [2].

Cannabis is the most widely used controlled substance among adults with chronic disease in the United States. CDC surveillance data indicate that approximately 18% of U.S. Adults with diabetes report past-year cannabis use [3]. Given that overlap, clinicians prescribing SGLT2 inhibitors will encounter this combination regularly.

Why There Is No Direct PK Trial

Dapagliflozin is metabolized primarily by UGT1A9 and UGT2B7, with minimal involvement of CYP3A4 or CYP2C9 [2]. Delta-9-tetrahydrocannabinol (THC), the primary psychoactive constituent of cannabis, is metabolized by CYP2C9 and CYP3A4, and cannabidiol (CBD) is a known inhibitor of CYP3A4 and CYP2C9 [4]. Because dapagliflozin largely bypasses those pathways, a traditional pharmacokinetic drug-drug interaction is unlikely. No sponsor has funded a dedicated crossover trial for this combination, and none appears on ClinicalTrials.gov as of the date of this writing.

That absence of PK data does not mean the combination is safe. The risks are pharmacodynamic, meaning they arise from overlapping physiological actions rather than altered drug levels.

The DKA Risk: Additive and Poorly Recognized

How SGLT2 Inhibitors Raise Ketones at Baseline

By promoting glucosuria, SGLT2 inhibitors lower circulating insulin concentrations and raise glucagon. That hormonal shift activates hormone-sensitive lipase, increases free fatty acid release, and accelerates hepatic ketogenesis. A pooled analysis of the dapagliflozin clinical program published in Diabetes Care found a DKA incidence of approximately 0.16 per 100 patient-years in patients with type 2 diabetes, substantially higher than background rates [5]. Many of those cases occurred at blood glucose concentrations below 250 mg/dL, the classic DKA threshold, which is why the FDA label warns providers not to rely on blood glucose alone for diagnosis [2].

How Cannabis Amplifies That Risk

Cannabis use, particularly in the context of cannabis hyperemesis syndrome (CHS) or simple cannabis-induced nausea, creates the exact physiological conditions that tip an SGLT2 inhibitor user into DKA:

• Reduced oral intake lowers carbohydrate availability, suppressing insulin further.
• Vomiting causes volume depletion, concentrating ketones and worsening acidosis.
• THC at high doses has been shown to suppress insulin secretion directly in rodent pancreatic islet preparations [6].

A 2020 case series in Diabetes Care described multiple patients on SGLT2 inhibitors who developed euglycemic DKA during episodes of cannabis-induced vomiting, with blood glucose values between 130 and 220 mg/dL [7]. The authors concluded that cannabis use should be elicited during every SGLT2 inhibitor initiation visit.

The HealthRX DKA Risk Stratification Framework for Farxiga + Cannabis Users

| Risk Tier | Profile | Recommended Action | |---|---|---| | Tier 1 (Low) | Type 2 DM, well-controlled, infrequent cannabis use, no nausea/vomiting | Continue both; counsel on DKA signs; provide written ketone-check protocol | | Tier 2 (Moderate) | Frequent cannabis use, history of CHS, low-carb diet, or intermittent fasting | Hold dapagliflozin on days of heavy use; check urine ketones every 48 hours | | Tier 3 (High) | Type 1 DM (off-label use), active nausea/vomiting, prior SGLT2-related DKA | Discontinue dapagliflozin; choose alternative agent |

Clinicians should document cannabis use status in the chart at each visit. The American Diabetes Association 2024 Standards of Care recommend routine screening for substance use in all adults with diabetes as part of psychosocial assessment [8].

Blood Pressure and Volume Status: A Second Additive Risk

Dapagliflozin's Hemodynamic Profile

Dapagliflozin lowers systolic blood pressure by roughly 3 to 4 mmHg through osmotic diuresis and natriuresis [9]. In the DECLARE-TIMI 58 trial (N=17,160), dapagliflozin reduced the rate of hospitalization for heart failure versus placebo (hazard ratio 0.73; 95% CI 0.61 to 0.88; P<0.001), but modest blood pressure reduction was a consistent finding across the trial [10]. Volume depletion is therefore a baseline pharmacological feature of the drug, not a rare adverse effect.

Cannabis and Blood Pressure: A Biphasic Pattern

Acute cannabis use causes an initial tachycardia and blood pressure rise followed by vasodilation and orthostatic hypotension, particularly when the user stands. A 2019 systematic review in the Journal of the American Heart Association (N=24 studies) found that acute cannabis use was associated with a two- to threefold increase in orthostatic hypotension events [11]. Combining that vasodilatory effect with dapagliflozin-induced volume depletion means the orthostatic drop may be clinically significant, especially in older adults or patients on antihypertensive therapy.

Patients should be counseled to sit before standing after cannabis use, to maintain adequate hydration, and to monitor blood pressure at home during the first four weeks of combined use.

Can I Drink on Farxiga? Alcohol and the Same Pathways

Alcohol is not cannabis, but the two substances share the mechanisms most relevant to Farxiga risk. Both suppress insulin secretion, promote osmotic diuresis, and cause vasodilation. Alcohol additionally inhibits gluconeogenesis, which can precipitate hypoglycemia in patients on other antidiabetic agents used alongside dapagliflozin.

The Farxiga prescribing information does not list alcohol as a contraindicated substance, but it does note that volume depletion and DKA risk may be worsened by reduced caloric intake [2]. A night of heavy drinking that includes vomiting carries essentially the same DKA trigger profile as cannabis-induced nausea. The ADA 2024 Standards of Care advise that "adults with diabetes who drink alcohol should do so in moderation (no more than one drink per day for women, two drinks per day for men) and always with food" [8].

Patients combining dapagliflozin with either alcohol or cannabis should receive the same written ketone-monitoring protocol: check urine or blood ketones if nausea, vomiting, or abdominal pain develops, and seek emergency care immediately if ketones are elevated.

Pharmacokinetic Details Clinicians Should Know

Dapagliflozin Metabolism Pathway

Dapagliflozin reaches peak plasma concentration (Tmax) approximately 2 hours after oral dosing. Its half-life is 12.9 hours. Glucuronidation via UGT1A9 produces the primary inactive metabolite, dapagliflozin 3-O-glucuronide, which accounts for roughly 61% of the dose excreted in urine [2]. Because UGT1A9 is expressed in the kidney and liver and is not significantly inhibited by CBD or THC at typical cannabis-use concentrations, plasma dapagliflozin levels are unlikely to change meaningfully with cannabis co-use.

What CBD Does to Other UGT Enzymes

CBD has demonstrated inhibition of UGT1A9 in in vitro hepatic microsome models [4]. However, the clinical significance of that inhibition at inhaled or oral cannabis doses used recreationally has not been established in human PK studies. Until those data exist, the conservative clinical assumption is that high-dose CBD products (above 300 mg/day, as used in the Epidiolex trials) may slightly raise dapagliflozin exposure, while typical recreational doses present minimal PK risk [12].

Renal Function Considerations

Dapagliflozin's glucose-lowering efficacy depends on adequate renal function. The FDA label specifies that the drug should not be initiated for glycemic control when estimated glomerular filtration rate (eGFR) is <45 mL/min/1.73 m² [2]. Chronic heavy cannabis use has been associated with renal vasoconstriction in case reports, though large prospective data are limited. Clinicians should recheck eGFR in patients reporting heavy cannabis use at every annual visit.

Monitoring Protocol for Patients Using Both

Patients established on Farxiga who use cannabis should follow a structured monitoring plan. The components below are drawn from published SGLT2 inhibitor safety guidance and FDA label recommendations [2][5]:

1. Ketone monitoring. Check urine or blood ketones any time nausea, vomiting, or abdominal pain occurs. Blood beta-hydroxybutyrate above 0.6 mmol/L warrants withholding the next dapagliflozin dose. Above 1.5 mmol/L with symptoms, seek emergency evaluation.
2. Blood pressure checks. Record lying and standing blood pressure weekly for the first month if cannabis use is regular. Report orthostatic drops greater than 20 mmHg systolic to the prescriber.
3. Hydration. Drink at least 2 liters of water daily. On days of cannabis use involving reduced appetite, add an electrolyte drink to offset the combined osmotic diuresis.
4. Sick-day protocol. Temporarily hold dapagliflozin on any day with persistent vomiting (more than two episodes) or inability to tolerate oral fluids. Resume only after tolerating at least 500 mL of fluid without vomiting.
5. Annual labs. BMP, eGFR, urinalysis with ketones, HbA1c at every annual visit. Cannabis use status should be documented.

Special Populations

Patients With Type 1 Diabetes Using Farxiga Off-Label

Dapagliflozin is FDA-approved only for type 2 diabetes, HFrEF, and CKD, but some clinicians prescribe it off-label for type 1 diabetes as an adjunct to insulin. The DKA rate in type 1 patients on SGLT2 inhibitors is substantially higher than in type 2, estimated at 4 to 6 per 100 patient-years in the inTandem3 trial of sotagliflozin (a dual SGLT1/2 inhibitor) [13]. Cannabis use in this population should be considered a relative contraindication to continued SGLT2 inhibitor therapy unless rigorous monitoring is in place.

Older Adults

Adults above age 65 who use Farxiga are already at elevated risk of volume depletion from age-related reductions in thirst perception and renal concentrating ability. Cannabis use in older adults is rising: a 2020 JAMA Internal Medicine study (N=15,000+) documented a 75% increase in past-year cannabis use among adults aged 65 and older between 2015 and 2018 [14]. The orthostatic hypotension risk in this population is not theoretical. Falls, fractures, and syncope are documented consequences.

Patients With Heart Failure Using Farxiga

In DAPA-HF (N=4,744), dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 26% versus placebo (hazard ratio 0.74; 95% CI 0.65 to 0.85; P<0.001) [15]. Patients with HFrEF taking dapagliflozin are frequently on additional diuretics (furosemide, metolazone), making the additive volume-depleting effects of cannabis particularly dangerous. Cannabis-associated tachycardia additionally increases myocardial oxygen demand in a population with compromised cardiac reserve.

What to Tell Your Patient

Clinicians should address the cannabis question directly at the initiation visit and at every follow-up. A script modeled on motivational interviewing principles can open the conversation without judgment:

"Some patients taking Farxiga also use cannabis, either medically or recreationally. I want to make sure you know about a specific risk: if cannabis causes nausea or vomiting, your body can develop a dangerous buildup of acid even when your blood sugar looks normal. Here is a card explaining when to check for ketones and when to call us."

The Endocrine Society's 2023 position statement on cannabis and endocrine health states that "clinicians should routinely inquire about cannabis use in patients with diabetes and document it as part of medication reconciliation" [16]. That standard applies directly to Farxiga prescribers.